MYL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,156.38 -- higher than 96.72% of US-listed equities with positive expected earnings growth.
Mylan NV's stock had its IPO on December 18, 1987, making it an older stock than 90.52% of US equities in our set.
With a price/earnings ratio of 146.16, Mylan NV P/E ratio is greater than that of about 96.44% of stocks in our set with positive earnings.
If you're looking for stocks that are quantitatively similar to Mylan NV, a group of peers worth examining would be PKI, CNMD, WAB, FMC, and AIN.
Mylan NV develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company was founded in 1961 and is based in Potters Bar, Hertfordshire.
MYL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for MYL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Mylan NV ranked in the 74th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 256.5%. As for the metrics that stood out in our discounted cash flow analysis of Mylan NV, consider:
42% of the company's capital comes from equity, which is greater than just 22.26% of stocks in our cash flow based forecasting set.
Relative to other stocks in its sector (Healthcare), Mylan NV has a reliance on debt greater than 90.28% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Mylan NV? See INVA, ALXN, AMEH, CVS, and PCRX.
Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto®, a biosimilar to Enbrel® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treatment of myasthenia gravis (an autoimmune disorder affecting skeletal muscles) in the third quarter of 2020. Will the company's pipeline candidates be successful in their clinical trials?
Today, Delaware Enhanced Global Dividend and Income Fund (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," declares a monthly distribution of $0.0485 per share. The monthly distribution is payable June 26, 2020, to shareholders of record at the close of business on June 19, 2020. The ex-dividend date will be June 18, 2020. As described below, the distribution rate has been decreased to 6.5% of the Fund’s average net asset value ("NAV") per share starting with the June 26, 2020 distribution.
After several postponed decisions, Mylan Inc (MYL) has announced that it is moving forward with a Botox biosimilar development program in collaboration with Revance Therapeutics (RVNC). On the news MYL rose 3% in Monday’s trading, RVNC was up 4%, and Botox owner AbbVie (ABBV) fell 2%.Feedback from the U.S. FDA in February 2019 indicated that the 351(k) regulatory pathway for an onabotulinumtoxinA product is viable, Revance said. Based on this meeting, along with the results from additional characterization and analysis, the two companies are now proceeding with the development program.“We are excited to move forward with Revance on a clear and achievable development pathway for what will potentially be the first biosimilar to BOTOX” said Mylan President Rajiv Malik. “This collaboration ...